Table 2.
Clinical Characteristics of Patients With Nonsquamous NSCLC Who Had the Results of PD-L1 IHC Stain
| Characteristics | All Patients | PD-L1 Positivea (TPS ≥ 1%) | PD-L1 Negative (TPS < 1%) | p |
|---|---|---|---|---|
| Total | 42 | 29 (69.0) | 13 (31.0) | |
| Age, median, y (range) | 64.1 (38.9–87.5) | 64.3 (38.9–85.8) | 63.9 (50.1–87.5) | 1.000b |
| Sex | 0.422c | |||
| Female | 9 | 5 (17.2) | 4 (30.8) | |
| Male | 33 | 24 (82.8) | 9 (69.2) | |
| Smoking status | 1.000c | |||
| Nonsmokers | 13 | 9 (31.0) | 4 (30.8) | |
| Smokers | 29 | 20 (69.0) | 9 (69.2) | |
| Stage | 0.501 | |||
| I–IIIa | 18 | 11 (37.9) | 7 (53.8) | |
| IIIb or IV | 24 | 18 (62.1) | 6 (46.2) | |
| Tumor | 0.540c | |||
| Adenocarcinoma | 39 | 26 (89.7) | 13 (100.0) | |
| Otherd | 3 | 3 (10.3) | 0 (0.0) | |
| Kras mutation | 0.317 | |||
| G12C | 21 | 13 (44.8) | 8 (61.5) | |
| Non-G12C | 21 | 16 (55.2) | 5 (38.5) |
Note: Values are given in number (%) unless indicated otherwise.
IHC, immunohistochemistry; NOS, not otherwise specified; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.
a
PD-L1 IHC by DAKO 22C3 and SP263.
b
By Mann-Whitney U test.
c
By Fisher’s exact test.
d
Two NSCLC-NOS and one pleomorphic carcinoma.